{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T17:37:48Z","timestamp":1781804268573,"version":"3.54.5"},"reference-count":152,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Multiple sclerosis (MS) is a chronic, autoimmune, demyelinating disease of the central nervous system (CNS). Microbes, including bacteria and certain viruses, particularly Epstein\u2013Barr virus (EBV), have been linked to the pathogenesis of MS. While there is currently no cure for MS, antibiotics and antivirals have been studied as potential treatment options due to their immunomodulatory ability that results in the regulation of the immune process. The current issue addressed in this systematic review is the effect of antimicrobials, including antibiotics, antivirals, and antiparasitic agents in animals and humans. We performed a comprehensive search of PubMed, Google Scholar, and Scopus for articles on antimicrobials in experimental autoimmune encephalomyelitis animal models of MS, as well as in people with MS (pwMS). In animal models, antibiotics tested included beta-lactams, minocycline, rapamycin, macrolides, and doxycycline. Antivirals included acyclovir, valacyclovir, and ganciclovir. Hydroxychloroquine was the only antiparasitic that was tested. In pwMS, we identified a total of 24 studies, 17 of them relevant to antibiotics, 6 to antivirals, and 1 relevant to antiparasitic hydroxychloroquine. While the effect of antimicrobials in animal models was promising, only minocycline and hydroxychloroquine improved outcome measures in pwMS. No favorable effect of the antivirals in humans has been observed yet. The number and size of clinical trials testing antimicrobials have been limited. Large, multicenter, well-designed studies are needed to further evaluate the effect of antimicrobials in MS.<\/jats:p>","DOI":"10.3390\/biomedicines11113069","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T01:56:29Z","timestamp":1700099789000},"page":"3069","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["From Animal Models to Clinical Trials: The Potential of Antimicrobials in Multiple Sclerosis Treatment"],"prefix":"10.3390","volume":"11","author":[{"given":"Muhammad Faraz","family":"Raghib","sequence":"first","affiliation":[{"name":"Department of Neurology, Wayne State University School of Medicine, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9382-1008","authenticated-orcid":false,"given":"Evanthia","family":"Bernitsas","sequence":"additional","affiliation":[{"name":"Department of Neurology, Wayne State University School of Medicine, Detroit, MI 48201, USA"},{"name":"Sastry Neuroimaging Laboratory, Department of Neurology, Wayne State University School of Medicine, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Rivera, V.M. (2018). Multiple Sclerosis: A Global Concern with Multiple Challenges in an Era of Advanced Therapeutic Complex Molecules and Biological Medicines. Biomedicines, 6.","DOI":"10.3390\/biomedicines6040112"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1177\/1352458517694432","article-title":"New insights into the burden and costs of multiple sclerosis in Europe","volume":"23","author":"Kobelt","year":"2017","journal-title":"Mult. Scler. J."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Bross, M., Hackett, M., and Bernitsas, E. (2020). Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21124312"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Quirant-S\u00e1nchez, B., Mansilla, M.J., Navarro-Barriuso, J., Presas-Rodr\u00edguez, S., Teniente-Serra, A., Fondelli, F., Ramo-Tello, C., and Mart\u00ednez-C\u00e1ceres, E. (2021). Combined Therapy of Vitamin D3-Tolerogenic Dendritic Cells and Interferon-\u03b2 in a Preclinical Model of Multiple Sclerosis. Biomedicines, 9.","DOI":"10.3390\/biomedicines9121758"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Bernitsas, E., Khan, O., Razmjou, S., Tselis, A., Bao, F., Caon, C., Millis, S., and Seraji-Bozorgzad, N. (2017). Cerebrospinal fluid humoral immunity in the differential diagnosis of multiple sclerosis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0181431"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Eva, L., Ple\u0219, H., Covache-Busuioc, R.-A., Glavan, L.A., Bratu, B.-G., Bordeianu, A., Dumitrascu, D.-I., Corlatescu, A.D., and Ciurea, A.V. (2023). A Comprehensive Review on Neuroimmunology: Insights from Multiple Sclerosis to Future Therapeutic Developments. Biomedicines, 11.","DOI":"10.3390\/biomedicines11092489"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Tarlinton, R.E., Martynova, E., Rizvanov, A.A., Khaiboullina, S., and Verma, S. (2020). Role of viruses in the pathogenesis of multiple sclerosis. Viruses, 12.","DOI":"10.3390\/v12060643"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ana.21117","article-title":"Environmental risk factors for multiple sclerosis. Part I: The role of infection","volume":"61","author":"Ascherio","year":"2007","journal-title":"Ann. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"12330","DOI":"10.1128\/JVI.01699-12","article-title":"Persistence of Epstein-Barr virus in self-reactive memory B cells","volume":"86","author":"Tracy","year":"2012","journal-title":"J. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/BOR.0b013e328362004d","article-title":"Multiple sclerosis: Autoimmunity and viruses","volume":"25","author":"Cusick","year":"2013","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Melzer, N., Meuth, S.G., Torres-Salazar, D., Bittner, S., Zozulya, A.L., Weidenfeller, C., Kotsiari, A., Stangel, M., Fahlke, C., and Wiendl, H. (2008). A \u03b2-lactam antibiotic dampens excitotoxic inflammatory CNS damage in a mouse model of multiple sclerosis. PLoS ONE, 3.","DOI":"10.1371\/annotation\/b898d6ee-801a-474e-9776-72e4da664b89"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1177\/1352458506070319","article-title":"The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: A pilot study","volume":"13","author":"Zabad","year":"2007","journal-title":"Mult. Scler."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000443361","article-title":"The role of antibiotics in gut microbiota modulation: The eubiotic effects of rifaximin","volume":"34","author":"Ponziani","year":"2016","journal-title":"Dig. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s11910-014-0492-2","article-title":"Gut microbiome and multiple sclerosis","volume":"14","author":"Bhargava","year":"2014","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.3748\/wjg.v23.i25.4491","article-title":"Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation","volume":"23","author":"Ponziani","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8168717","DOI":"10.1155\/2018\/8168717","article-title":"Gut Microbiota in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Current Applications and Future Perspectives","volume":"2018","author":"Chu","year":"2018","journal-title":"Mediat. Inflamm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.4049\/jimmunol.0900747","article-title":"Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis","volume":"183","author":"Mielcarz","year":"2009","journal-title":"J. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/nn.4030","article-title":"Host microbiota constantly control maturation and function of microglia in the CNS","volume":"18","author":"Erny","year":"2015","journal-title":"Nat. Neurosci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/nature08530","article-title":"Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43","volume":"461","author":"Maslowski","year":"2009","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/nm.4106","article-title":"Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor","volume":"22","author":"Rothhammer","year":"2016","journal-title":"Nat. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e774","DOI":"10.1038\/tp.2016.42","article-title":"Regulation of prefrontal cortex myelination by the microbiota","volume":"6","author":"Hoban","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cell.2023.03.008","article-title":"Multiple sclerosis: Neuroimmune crosstalk and therapeutic targeting","volume":"186","author":"Charabati","year":"2023","journal-title":"Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1004795","DOI":"10.3389\/fimmu.2023.1004795","article-title":"Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic","volume":"14","author":"Maillart","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/jon.12824","article-title":"Multimodal MRI Response to Fingolimod in Multiple Sclerosis: A Nonrandomized, Single Arm, Observational Study","volume":"31","author":"Bernitsas","year":"2021","journal-title":"J. Neuroimaging"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s40263-022-00939-9","article-title":"Efficacy and Safety of Multiple Sclerosis Drugs Approved Since 2018 and Future Developments","volume":"36","author":"Faissner","year":"2022","journal-title":"CNS Drugs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"ref_29","unstructured":"Centre for Reviews and Dissemination (2009, March 04). Systematic Reviews: CRD\u2019s Guidance for Undertaking Reviews in Health Care. Available online: http:\/\/www.york.ac.uk\/inst\/crd\/SysRev\/!SSL!\/WebHelp\/SysRev3.htm."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria\u201d","volume":"58","author":"Polman","year":"2005","journal-title":"Ann. Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nature03180","article-title":"\u03b2-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression","volume":"433","author":"Rothstein","year":"2005","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S1474-4422(16)30165-X","article-title":"Mechanisms of glutamate toxicity in multiple sclerosis: Biomarker and therapeutic opportunities","volume":"15","author":"Macrez","year":"2016","journal-title":"Lancet Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1073\/pnas.1215722110","article-title":"Beta-lactam antibiotics modulate T-cell functions and gene expression via covalent binding to cellular albumin","volume":"110","author":"Mor","year":"2013","journal-title":"Proc. Nat. Acad. Sci. USA"},{"key":"ref_36","first-page":"558","article-title":"Single-dose plasma and cerebrospinal fluid pharmacokinetics of ceftriaxone in infants and children","volume":"2","author":"Reed","year":"1983","journal-title":"Clin. Pharm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bbr.2015.08.011","article-title":"Synergistic effects of ceftriaxone and erythropoietin on neuronal and behavioral deficits in an MPTP-induced animal model of Parkinson\u2019s disease dementia","volume":"294","author":"Huang","year":"2015","journal-title":"Behav. Brain Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1016\/j.neurobiolaging.2015.04.005","article-title":"Ceftriaxone ameliorates tau pathology and cognitive decline via restoration of glial glutamate transporter in a mouse model of Alzheimer\u2019s disease","volume":"36","author":"Zumkehr","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3389\/fnins.2019.00236","article-title":"Repurposing of the \u03b2-lactam antibiotic, ceftriaxone for neurological disorders: A review","volume":"13","author":"Yimer","year":"2019","journal-title":"Front. Neurosci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/aje\/kwj123","article-title":"Antibiotic use and risk of multiple sclerosis","volume":"163","author":"Alonso","year":"2006","journal-title":"Am. J. Epidemiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/aje\/kwr201","article-title":"Use of penicillin and other antibiotics and risk of multiple sclerosis: A population-based case-control study","volume":"174","author":"Nielsen","year":"2011","journal-title":"Am. J. Epidemiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1080\/03007995.2017.1325575","article-title":"Allergies, antibiotics use, and multiple sclerosis","volume":"33","author":"Ren","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1177\/13524585231185045","article-title":"Exposure to systemic antibiotics in outpatient care and the risk of multiple sclerosis","volume":"29","author":"Viitala","year":"2023","journal-title":"Mult. Scler."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1001\/archneurol.2010.191","article-title":"Prospects for minocycline neuroprotection","volume":"67","author":"Plane","year":"2010","journal-title":"Arch. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Panizzutti, B., Skvarc, D., Lin, S., Croce, S., Meehan, A., Bortolasci, C.C., Marx, W., Walker, A.J., Hasebe, K., and Kavanagh, B.E. (2023). Minocycline as Treatment for Psychiatric and Neurological Conditions: A Systematic Review and Meta-Analysis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065250"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1570-0232(03)00247-2","article-title":"Liquid chromatographic determination of minocycline in brain-to-plasma distribution studies in the rat","volume":"791","author":"Colovic","year":"2003","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"14014","DOI":"10.1073\/pnas.93.24.14014","article-title":"A novel mechanism of action of tetracyclines: Effects on nitric oxide synthases","volume":"93","author":"Amin","year":"1996","journal-title":"Proc. Nati Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.bcp.2009.07.028","article-title":"Mitochondria and calcium flux as targets of neuroprotection caused by minocycline in cerebellar granule cells","volume":"79","author":"Karachitos","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1089\/ars.2007.1511","article-title":"Neuronal apoptosis in neurodegeneration","volume":"9","author":"Okouchi","year":"2007","journal-title":"Antioxid. Redox Signal"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2011.04.006","article-title":"The prospects of minocycline in multiple sclerosis","volume":"235","author":"Chen","year":"2011","journal-title":"J. Neuroimmunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"106237","DOI":"10.1016\/j.ejps.2022.106237","article-title":"The potential use of tetracyclines in neurodegenerative diseases and the role of nano-based drug delivery systems","volume":"175","author":"Rahmani","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"739186","DOI":"10.3389\/fimmu.2021.739186","article-title":"Tetracyclines Diminish In Vitro IFN-\u03b3 and IL-17-Producing Adaptive and Innate Immune Cells in Multiple Sclerosis","volume":"12","author":"Florou","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1474-4422(04)00937-8","article-title":"The promise of minocycline in neurology","volume":"3","author":"Yong","year":"2004","journal-title":"Lancet Neurol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Matsukawa, N., Yasuhara, T., Hara, K., Xu, L., Maki, M., Yu, G., Kaneko, Y., Ojika, K., Hess, D.C., and Borlongan, C.V. (2009). Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke. BMC Neurosci., 10.","DOI":"10.1186\/1471-2202-10-126"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10863-010-9271-1","article-title":"Minocycline chelates Ca2+, binds to membranes, and depolarizes mitochondria by formation of Ca2+-dependent ion channels","volume":"42","author":"Antonenko","year":"2010","journal-title":"Bioenergy Biomembr."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/TP.0b013e3181cbe041","article-title":"Minocycline promotes long-term survival of neuronal transplant in the brain by inhibiting late microglial activation and T-cell recruitment","volume":"89","author":"Plat","year":"2010","journal-title":"Transplantation"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2174\/1874467210801010068","article-title":"Immunomodulatory properties of antibiotics","volume":"1","author":"Tauber","year":"2008","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.4049\/jimmunol.1600436","article-title":"Impact of Minocycline on Extracellular Matrix Metalloproteinase Inducer, a Factor Implicated in Multiple Sclerosis Immunopathogenesis","volume":"197","author":"Hahn","year":"2016","journal-title":"J. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-3083.2005.01649.x","article-title":"Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis","volume":"62","author":"Caggiula","year":"2005","journal-title":"Scand. J. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejphar.2012.04.043","article-title":"Minocycline up-regulates the expression of brain-derived neurotrophic factor and nerve growth factor in experimental autoimmune encephalomyelitis","volume":"686","author":"Chen","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/01.wnf.0000150867.98887.3e","article-title":"The potential of minocycline for neuroprotection in human neurologic disease","volume":"27","author":"Zemke","year":"2004","journal-title":"Clin. Neuropharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/ana.10092","article-title":"Inhibition of autoimmune encephalomyelitis by a tetracycline","volume":"51","author":"Popovic","year":"2002","journal-title":"Ann. Neurol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jneuroim.2009.11.009","article-title":"Minocycline attenuates experimental autoimmune encephalomyelitis in rats by reducing T cell infiltration into the spinal cord","volume":"219","author":"Nikodemova","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/brain\/awf133","article-title":"Targeting leukocyte MMPs and transmigration: Minocycline as a potential therapy for multiple sclerosis","volume":"125","author":"Brundula","year":"2002","journal-title":"Brain"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bbi.2016.11.010","article-title":"Selective dentate gyrus disruption causes memory impairment at the early stage of experimental multiple sclerosis","volume":"60","author":"Planche","year":"2017","journal-title":"Brain Behav. Immun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41583-019-0260-z","article-title":"Dentate gyrus circuits for encoding, retrieval and discrimination of episodic memories","volume":"21","author":"Hainmueller","year":"2020","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1177\/1352458517728811","article-title":"Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease?","volume":"24","author":"Faissner","year":"2018","journal-title":"Mult. Scler."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1021\/pr300428e","article-title":"Minocycline effects on the cerebrospinal fluid proteome of experimental autoimmune encephalomyelitis rats","volume":"11","author":"Stoop","year":"2012","journal-title":"J. Proteome Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.nbd.2006.10.022","article-title":"Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation","volume":"25","author":"Maier","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1177\/1352458509106779","article-title":"Glatiramer acetate in combination with minocycline in patients with relapsing-remitting multiple sclerosis: Results of a Canadian, multicenter, double-blind, placebo-controlled trial","volume":"15","author":"Metz","year":"2009","journal-title":"Mult. Scler."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/ene.12953","article-title":"Minocycline added to subcutaneous interferon \u03b2-1a in multiple sclerosis: Randomized RECYCLINE study","volume":"23","author":"Sellebjerg","year":"2016","journal-title":"Eur. J. Neurol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/ana.20111","article-title":"Minocycline reduces gadolinium enhancing magnetic resonance imaging lesions in multiple sclerosis","volume":"55","author":"Metz","year":"2004","journal-title":"Ann. Neurol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1017\/S0317167100008611","article-title":"Pilot study of minocycline in relapsing-remitting multiple sclerosis","volume":"35","author":"Zhang","year":"2008","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa1608889","article-title":"Trial of minocycline in a clinically isolated syndrome of multiple sclerosis","volume":"376","author":"Metz","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1177\/13524585221109761","article-title":"Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels","volume":"28","author":"Metz","year":"2022","journal-title":"Mult. Scler."},{"key":"ref_76","first-page":"22","article-title":"Can tetracyclines ensure help in multiple sclerosis immunotherapy?","volume":"7","author":"Thome","year":"2021","journal-title":"J. Clin. Transl. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archneurol.2007.41","article-title":"Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: An open-label trial","volume":"65","author":"Minagar","year":"2008","journal-title":"Arch. Neurol."},{"key":"ref_78","first-page":"70","article-title":"Efficacy of doxycycline as add-on to interferon beta-1a in treatment of multiple sclerosis","volume":"11","author":"Mazdeh","year":"2012","journal-title":"Iran. J. Neurol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1007\/s11064-011-0522-2","article-title":"Doxycycline attenuates peripheral inflammation in rat experimental autoimmune neuritis","volume":"36","author":"Yi","year":"2011","journal-title":"Neurochem. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/TP.0b013e3182445e9d","article-title":"Generic immunosuppression in solid organ transplantation: A Canadian perspective","volume":"93","author":"Harrison","year":"2012","journal-title":"Transplantation"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4049\/jimmunol.164.1.419","article-title":"Kinetics and cellular origin of cytokines in the central nervous system: Insight into mechanisms of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis","volume":"164","author":"Juedes","year":"2000","journal-title":"J. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrn3068","article-title":"Fighting neurodegeneration with rapamycin: Mechanistic insights","volume":"12","author":"Vila","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Vakrakou, A.G., Alexaki, A., Brinia, M.E., Anagnostouli, M., Stefanis, L., and Stathopoulos, P. (2022). The mTOR Signaling Pathway in Multiple Sclerosis; from Animal Models to Human Data. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158077"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1007\/s11064-017-2296-7","article-title":"Rapamycin Ameliorates Experimental Autoimmune Encephalomyelitis by Suppressing the mTOR-STAT3 Pathway","volume":"42","author":"Hou","year":"2017","journal-title":"Neurochem. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jneuroim.2010.01.001","article-title":"Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation","volume":"220","author":"Esposito","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jneuroim.2011.12.018","article-title":"Rapamycin reduces clinical signs and neuropathic pain in a chronic model of experimental autoimmune encephalomyelitis","volume":"243","author":"Lisi","year":"2012","journal-title":"J. Neuroimmunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1007\/s12035-016-9840-3","article-title":"Rapamycin Augments Immunomodulatory Properties of Bone Marrow-Derived Mesenchymal Stem Cells in Experimental Autoimmune Encephalomyelitis","volume":"54","author":"Togha","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"117747","DOI":"10.1016\/j.lfs.2020.117747","article-title":"Rapamycin and MCC950 modified gut microbiota in experimental autoimmune encephalomyelitis mouse by brain gut axis","volume":"253","author":"Xu","year":"2020","journal-title":"Life Sci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.msard.2018.08.009","article-title":"Promising effect of rapamycin on multiple sclerosis","volume":"26","author":"Bagherpour","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_90","first-page":"S46","article-title":"The effect of oral temsirolimus on new magnetic resonance imaging scan lesions, brain atrophy, and the number of relapses in multiple sclerosis: Results from a randomised, controlled clinical trial","volume":"252","author":"Kappos","year":"2005","journal-title":"J. Neurol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/ana.21958","article-title":"Long-interval T2-weighted subtraction magnetic resonance imaging: A powerful new outcome measure in multiple sclerosis trials","volume":"67","author":"Moraal","year":"2010","journal-title":"Ann. Neurol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/ane.12839","article-title":"Trials of antivirals in the treatment of multiple sclerosis","volume":"136","author":"Lycke","year":"2017","journal-title":"Acta Neurol. Scand."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"102540","DOI":"10.1016\/j.msard.2020.102540","article-title":"Could SARS-CoV2 affect MS progression?","volume":"46","author":"Romani","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00415-007-0684-7","article-title":"Multiple sclerosis therapy: An update on recently finished trials","volume":"254","author":"Kleinschnitz","year":"2007","journal-title":"J. Neurol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1001\/archneur.1983.04050070036006","article-title":"Epstein-Barr virus infection and antibody synthesis in patients with multiple sclerosis","volume":"40","author":"Bray","year":"1983","journal-title":"Arch. Neurol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1212\/WNL.35.3.435","article-title":"Epstein-Barr nuclear antigen and viral capsid antigen antibody titers in multiple sclerosis","volume":"35","author":"Larsen","year":"1985","journal-title":"Neurology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/jnnp-2020-322941","article-title":"Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis","volume":"91","author":"Abrahamyan","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1001\/jama.286.24.3083","article-title":"Epstein-Barr virus antibodies and risk of multiple sclerosis: A prospective study","volume":"286","author":"Ascherio","year":"2001","journal-title":"JAMA"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"577935","DOI":"10.1016\/j.jneuroim.2022.577935","article-title":"MINI-review of Epstein-Barr virus involvement in multiple sclerosis etiology and pathogenesis","volume":"371","author":"Aloisi","year":"2022","journal-title":"J. Neuroimmunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1177\/1352458520907901","article-title":"Systematic review and meta-analysis of the association between Epstein\u2013Barr virus, multiple sclerosis and other risk factors","volume":"26","author":"Jacobs","year":"2020","journal-title":"Mult. Scler."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.it.2003.09.005","article-title":"Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases","volume":"24","author":"Pender","year":"2003","journal-title":"Trends Immunol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0165-5728(00)00181-8","article-title":"Mistaken self, a novel model that links microbial infections with myelin-directed autoimmunity in multiple sclerosis","volume":"105","author":"Bajramovic","year":"2000","journal-title":"J. Neuroimmunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"102332","DOI":"10.1016\/j.jaut.2019.102332","article-title":"Epstein Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model","volume":"106","author":"Jog","year":"2020","journal-title":"J. Autoimmun."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41586-022-04432-7","article-title":"Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM","volume":"603","author":"Lanz","year":"2022","journal-title":"Nature"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"103282","DOI":"10.1016\/j.msard.2021.103282","article-title":"The cellular immune response against Epstein-Barr virus decreases during ocrelizumab treatment","volume":"56","author":"Pham","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"102569","DOI":"10.1016\/j.msard.2020.102569","article-title":"Tenofovir as a treatment option for multiple sclerosis","volume":"46","author":"Torkildsen","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/jnnp-2014-307932","article-title":"HIV and lower risk of multiple sclerosis: Beginning to unravel a mystery using a record-linked database study","volume":"86","author":"Gold","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.msard.2018.06.002","article-title":"A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study","volume":"24","author":"Gold","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1084\/jem.20120696","article-title":"Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation","volume":"211","author":"Ding","year":"2014","journal-title":"J. Exp. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/BF00868517","article-title":"Acyclovir treatment of relapsing-remitting multiple sclerosis: A randomized, placebo-controlled, double-blind study","volume":"243","author":"Lycke","year":"1996","journal-title":"J. Neurol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1212\/WNL.58.1.31","article-title":"A randomized, double-blind, placebo-controlled MRI study of anti\u2013herpes virus therapy in MS","volume":"58","author":"Bech","year":"2002","journal-title":"Neurology"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1191\/1352458505ms1185oa","article-title":"A randomized clinical trial of valacyclovir in multiple sclerosis","volume":"11","author":"Friedman","year":"2005","journal-title":"Mult. Scler."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jns.2015.08.1525","article-title":"Hydroxychloroquine reduces microglial activity and attenuates experimental autoimmune encephalomyelitis","volume":"358","author":"Koch","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s13311-020-01002-5","article-title":"Combination of Hydroxychloroquine and Indapamide Attenuates Neurodegeneration in Models Relevant to Multiple Sclerosis","volume":"18","author":"Brown","year":"2021","journal-title":"Neurotherapeutics"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ana.26239","article-title":"Hydroxychloroquine for Primary Progressive Multiple Sclerosis","volume":"90","author":"Koch","year":"2021","journal-title":"Ann. Neurol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/1531-8249(200005)47:5<652::AID-ANA15>3.0.CO;2-5","article-title":"Evidence for infection with Chlamydia pneumoniae in a subgroup of patients with multiple sclerosis","volume":"47","author":"Bendl","year":"2000","journal-title":"Ann. Neurol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1080\/08820130903062194","article-title":"Macrolide antibiotics aggravate experimental autoimmune encephalomyelitis and inhibit inducible nitric oxide synthase","volume":"38","author":"Wang","year":"2009","journal-title":"Immunol. Investig."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jns.2005.03.042","article-title":"Pilot study to examine the effect of antibiotic therapy on MRI outcomes in RRMS","volume":"234","author":"Sriram","year":"2005","journal-title":"J. Neurol. Sci."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s15010-006-5114-8","article-title":"Long-term Antibiotic Treatment with Roxithromycin in Patients with Multiple Sclerosis","volume":"34","author":"Woessner","year":"2006","journal-title":"Infection"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2019). Cochrane Handbook for Systematic Reviews of Interventions, John Wiley & Sons. [2nd ed.].","DOI":"10.1002\/9781119536604"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Bernitsas, E. (2018). Pathophysiology and Imaging Diagnosis of Demyelinating Disorders. Brain Sci., 8.","DOI":"10.3390\/brainsci8030044"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"de Oliveira, M., Santinelli, F.B., Lisboa-Filho, P.N., and Barbieri, F.A. (2023). The Blood Concentration of Metallic Nanoparticles Is Related to Cognitive Performance in People with Multiple Sclerosis: An Exploratory Analysis. Biomedicines, 11.","DOI":"10.3390\/biomedicines11071819"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Al-Shammri, S., Chattopadhyay, A., Hanah, M.G., Doi, S., and Akanji, A. (2023). Association of Blood Levels of Vitamin D and Its Binding Protein with Clinical Phenotypes of Multiple Sclerosis. Biomedicines, 11.","DOI":"10.3390\/biomedicines11071808"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Dustin, E., Suarez-Pozos, E., Stotesberry, C., Qiu, S., Palavicini, J.P., Han, X., and Dupree, J.L. (2023). Compromised Myelin and Axonal Molecular Organization Following Adult-Onset Sulfatide Depletion. Biomedicines, 11.","DOI":"10.3390\/biomedicines11051431"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Tanaka, M., and V\u00e9csei, L. (2020). Monitoring the Redox Status in Multiple Sclerosis. Biomedicines, 8.","DOI":"10.20944\/preprints202007.0737.v3"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Memon, A.B., Javed, A., Caon, C., Srivastawa, S., Bao, F., Bernitsas, E., Chorostecki, J., Tselis, A., Seraji-Bozorgzad, N., and Khan, O. (2018). Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0190425"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"120459","DOI":"10.1016\/j.jns.2022.120459","article-title":"Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: A review","volume":"443","author":"Sharma","year":"2022","journal-title":"J. Neurol. Sci."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"577721","DOI":"10.1016\/j.jneuroim.2021.577721","article-title":"Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis","volume":"360","author":"Sriwastava","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Rivera, V.M. (2021). Editorial of Special Issue \u201cMultiple Sclerosis: Diagnosis and Treatment II\u201d. Biomedicines, 9.","DOI":"10.3390\/biomedicines9111605"},{"key":"ref_130","unstructured":"Marchand, D.K., and Butcher, R. (2019). Minocycline for Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome: A Review of Clinical Effectiveness and Guidelines."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/ene.15588","article-title":"Serum neurofilament-light and glial fibrillary acidic protein levels in hydroxychloroquine-treated primary progressive multiple sclerosis","volume":"30","author":"Silva","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Poly\u00e1k, H., Galla, Z., N\u00e1n\u00e1si, N., Cseh, E.K., Rajda, C., Veres, G., Spekker, E., Szab\u00f3, \u00c1., Kliv\u00e9nyi, P., and Tanaka, M. (2023). The Tryptophan-Kynurenine Metabolic System Is Suppressed in Cuprizone-Induced Model of Demyelination Simulating Progressive Multiple Sclerosis. Biomedicines, 11.","DOI":"10.3390\/biomedicines11030945"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Macaron, G., and Ontaneda, D. (2019). Diagnosis and Management of Progressive Multiple Sclerosis. Biomedicines, 7.","DOI":"10.3390\/biomedicines7030056"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Touil, H., Li, R., Zuroff, L., Moore, C.S., Healy, L., Cignarella, F., Piccio, L., Ludwin, S., Prat, A., and Gommerman, J. (2023). Cross-talk between B cells, microglia and macrophages, and implications to central nervous system compartmentalized inflammation and progressive multiple sclerosis. EBioMedicine, 96.","DOI":"10.1016\/j.ebiom.2023.104789"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Correale, J., Marrodan, M., and Ysrraelit, M.C. (2019). Mechanisms of Neurodegeneration and Axonal Dysfunction in Progressive Multiple Sclerosis. Biomedicines, 7.","DOI":"10.3390\/biomedicines7010014"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1197212","DOI":"10.3389\/fneur.2023.1197212","article-title":"Impact of aging on treatment considerations for multiple sclerosis patients","volume":"14","author":"Macaron","year":"2023","journal-title":"Front. Neurol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.0105-2896.2005.00271.x","article-title":"Human immunosenescence: Is it infectious?","volume":"205","author":"Pawelec","year":"2005","journal-title":"Immunol. Rev."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"854390","DOI":"10.3389\/fneur.2022.854390","article-title":"Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure","volume":"13","author":"Manouchehri","year":"2022","journal-title":"Front. Neurol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/WCO.0000000000000701","article-title":"Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis","volume":"32","author":"Schweitzer","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.3389\/fimmu.2019.02247","article-title":"Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention","volume":"10","author":"Aiello","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/19490976.2017.1349041","article-title":"Gut microbiome in multiple sclerosis: The players involved and the roles they play","volume":"8","author":"Shahi","year":"2017","journal-title":"Gut Microbes"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1177\/1352458520928301","article-title":"Gut commensals, dysbiosis, and immune response imbalance in the pathogenesis of multiple sclerosis","volume":"27","author":"Brown","year":"2021","journal-title":"Mult. Scler."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s11940-015-0344-7","article-title":"The gut microbiome in multiple sclerosis","volume":"17","author":"Mielcarz","year":"2015","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Bicknell, B., Liebert, A., Borody, T., Herkes, G., McLachlan, C., and Kiat, H. (2023). Neurodegenerative and Neurodevelopmental Diseases and the Gut-Brain Axis: The Potential of Therapeutic Targeting of the Microbiome. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119577"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e143774","DOI":"10.1172\/JCI143774","article-title":"Targeting the gut to treat multiple sclerosis","volume":"131","author":"Ghezzi","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.2174\/1570159X19666210217084827","article-title":"Modulating Gut Microbiota: An Emerging Approach in the Prevention and Treatment of Multiple Sclerosis","volume":"19","author":"Ullah","year":"2021","journal-title":"Curr. Neuropharmacol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.3389\/fimmu.2019.01374","article-title":"Manipulation of Gut Microbiota Influences Immune Responses, Axon Preservation, and Motor Disability in a Model of Progressive Multiple Sclerosis","volume":"10","author":"Mestre","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cyto.2018.10.016","article-title":"The protective effect of rifampicin on behavioral deficits, biochemical, and neuropathological changes in a cuprizone model of demyelination","volume":"113","author":"Zahednasab","year":"2019","journal-title":"Cytokine"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1212\/CPJ.0000000000000710","article-title":"Technology-enabled assessments to enhance multiple sclerosis clinical care and research","volume":"10","author":"Macaron","year":"2020","journal-title":"Neurol. Clin. Pract."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"101525","DOI":"10.1016\/j.msard.2019.101525","article-title":"Technology-enabled comprehensive characterization of multiple sclerosis in clinical practice","volume":"38","author":"Baldassari","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1207617","DOI":"10.3389\/fneur.2023.1207617","article-title":"Aging in multiple sclerosis: From childhood to old age, etiopathogenesis, and unmet needs: A narrative review","volume":"14","author":"Capasso","year":"2023","journal-title":"Front. Neurol."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/11\/11\/3069\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:23:51Z","timestamp":1760131431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/11\/11\/3069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":152,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["biomedicines11113069"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines11113069","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,16]]}}}